Carbamazepine Hinders Warfarin Anticoagulation
Carbamazepine co-treatment linked to subtherapeutic anticoagulative effect of warfarin.
(HealthDay News) -- For warfarin-treated patients, carbamazepine co-treatment is associated with subtherapeutic anticoagulative effect and increased warfarin dose requirements, according to a study published online in the Journal of Thrombosis and Haemostasis.
Buster Mannheimer, MD, PhD, from the Karolinska Institutet in Stockholm, and colleagues used data from 3 nationwide registries to examine the effect of carbamazepine on warfarin anticoagulation and warfarin maintenance doses in a retrospective cohort study. Warfarin doses were compared for 166 patients between 2 and 4-week periods before and 10 to 13 weeks after initiating co-treatment with carbamazepine.
The researchers found that during carbamazepine treatment the average warfarin doses were 49% higher. Upon initiation of carbamazepine, international normalized ratio (INR) decreased; during the fifth week of co-treatment, subtherapeutic INR levels were seen in 79% of patients. In 59 and 17% of patients, warfarin maintenance dose increases exceeded 50 and 100%, respectively.
"Four out of 5 warfarin-treated patients initiating co-medication with carbamazepine experienced subtherapeutic anticoagulative effect within 3 to 5 weeks," the authors write. "In order to avoid thrombosis and ischemic stroke, the initiation of carbamazepine should be accompanied by close INR monitoring to better meet the anticipated increase in dose demand."